On July 11, 2024, Shanghai Escugen Biotechnology Co., Ltd. ("Escugen") announced that the first patient has been dosed in the Phase III clinical trial (ESG401-301) of its independently developed innovative drug, ESG401 Injection. This trial aims to treat hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic breast cancer that has previously received at least one line of systemic chemotherapy. This significant milestone marks another important achievement in the development process of ESG401 by Escugen.

The B cell activating factor receptor BAFF-R (B cell activating factor of the TNF-family receptor) is a member of the TNF receptor superfamily, which is primarily involved in the development of B lymphocytes and the survival of mature B cells.